英国癌症研究所调控细胞分裂的MPS1新型抑制剂具有克服侵袭性乳腺癌耐药的潜力

2019-10-07 不详 MedSci原创

​英国癌症研究所(ICR)的一项新研究表明,阻断MPS1的新药BOS172722可以阻止癌症对化疗产生耐药性,重新激发对化疗的反应,从而用于治疗侵袭性乳腺癌。目前,这种新疗法的第一项临床试验正在实体瘤癌症中进行,包括侵袭性三阴性乳腺癌。研究人员认为,它还可能对其他快速增长的癌症(例如卵巢癌)有效。

英国癌症研究所(ICR)的一项新研究表明,阻断MPS1的新药BOS172722可以阻止癌症对化疗产生耐药性,重新激发对化疗的反应,从而用于治疗侵袭性乳腺癌。目前,这种新疗法的第一项临床试验正在实体瘤癌症中进行,包括侵袭性三阴性乳腺癌。研究人员认为,它还可能对其他快速增长的癌症(例如卵巢癌)有效。


MPS1调控细胞分裂过程中染色体在子细胞之间的正确分布,通过使用新药阻断MPS1,癌细胞可以通过错误染色体数目引起的细胞分裂而加速死亡。ICR研究人员发现,用MPS1抑制剂处理过的癌细胞仅需11分钟即可发生细胞分裂,而没有使用该药物则需要52分钟。来自三阴性乳腺癌,卵巢癌和肺癌的快速分裂细胞对阻断MPS1的作用特别敏感。


当前,三阴性乳腺癌患者接受紫杉烷化学疗法(例如紫杉醇)作为他们的标准护理。紫杉醇还影响细胞分裂过程中染色体的分布,但会阻止细胞分裂,从而导致细胞死亡。然而,一些细胞逃脱了对药物的抗性并引起更多的肿瘤。


紫杉醇与BOS172722联合治疗可显着减少细胞分裂时间,从单独使用紫杉醇的110分钟减少到与BOS172722组合的15分钟。用该组合物处理的所有细胞均分裂为染色体异常,并因此死亡,而仅紫杉醇可存活40%。


当与紫杉醇联合用于小鼠时,MPS1抑制剂在较低剂量下也有效,并且在几乎完全消除肿瘤的剂量下被小鼠很好地耐受。


原始出处:


http://www.firstwordpharma.com/node/1671993?tsid=4#axzz61d2Qpex3


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1801064, encodeId=d601180106433, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Mon Dec 02 08:21:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984954, encodeId=d2dd1984954c7, content=<a href='/topic/show?id=d3811218054' target=_blank style='color:#2F92EE;'>#MPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12180, encryptionId=d3811218054, topicName=MPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Dec 16 11:21:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797822, encodeId=aca91e978222a, content=<a href='/topic/show?id=555523e73fc' target=_blank style='color:#2F92EE;'>#乳腺癌耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23773, encryptionId=555523e73fc, topicName=乳腺癌耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Sun Dec 08 23:21:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852145, encodeId=cc3a1852145da, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 01 00:21:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984514, encodeId=3bd7198451463, content=<a href='/topic/show?id=23002e000b3' target=_blank style='color:#2F92EE;'>#侵袭性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27000, encryptionId=23002e000b3, topicName=侵袭性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Jan 10 11:21:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811220, encodeId=14a5181122076, content=<a href='/topic/show?id=b0558e110be' target=_blank style='color:#2F92EE;'>#英国癌症研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87110, encryptionId=b0558e110be, topicName=英国癌症研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed Dec 18 14:21:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366341, encodeId=9a0813663416d, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Wed Oct 09 01:21:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514195, encodeId=dc181514195a7, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Wed Oct 09 01:21:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557180, encodeId=0678155e180c7, content=<a href='/topic/show?id=f611e7814e8' target=_blank style='color:#2F92EE;'>#细胞分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77814, encryptionId=f611e7814e8, topicName=细胞分裂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126314868296, createdName=wshxjq, createdTime=Wed Oct 09 01:21:00 CST 2019, time=2019-10-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1801064, encodeId=d601180106433, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Mon Dec 02 08:21:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984954, encodeId=d2dd1984954c7, content=<a href='/topic/show?id=d3811218054' target=_blank style='color:#2F92EE;'>#MPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12180, encryptionId=d3811218054, topicName=MPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Dec 16 11:21:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797822, encodeId=aca91e978222a, content=<a href='/topic/show?id=555523e73fc' target=_blank style='color:#2F92EE;'>#乳腺癌耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23773, encryptionId=555523e73fc, topicName=乳腺癌耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Sun Dec 08 23:21:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852145, encodeId=cc3a1852145da, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 01 00:21:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984514, encodeId=3bd7198451463, content=<a href='/topic/show?id=23002e000b3' target=_blank style='color:#2F92EE;'>#侵袭性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27000, encryptionId=23002e000b3, topicName=侵袭性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Jan 10 11:21:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811220, encodeId=14a5181122076, content=<a href='/topic/show?id=b0558e110be' target=_blank style='color:#2F92EE;'>#英国癌症研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87110, encryptionId=b0558e110be, topicName=英国癌症研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed Dec 18 14:21:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366341, encodeId=9a0813663416d, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Wed Oct 09 01:21:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514195, encodeId=dc181514195a7, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Wed Oct 09 01:21:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557180, encodeId=0678155e180c7, content=<a href='/topic/show?id=f611e7814e8' target=_blank style='color:#2F92EE;'>#细胞分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77814, encryptionId=f611e7814e8, topicName=细胞分裂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126314868296, createdName=wshxjq, createdTime=Wed Oct 09 01:21:00 CST 2019, time=2019-10-09, status=1, ipAttribution=)]
    2019-12-16 仁医06
  3. [GetPortalCommentsPageByObjectIdResponse(id=1801064, encodeId=d601180106433, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Mon Dec 02 08:21:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984954, encodeId=d2dd1984954c7, content=<a href='/topic/show?id=d3811218054' target=_blank style='color:#2F92EE;'>#MPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12180, encryptionId=d3811218054, topicName=MPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Dec 16 11:21:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797822, encodeId=aca91e978222a, content=<a href='/topic/show?id=555523e73fc' target=_blank style='color:#2F92EE;'>#乳腺癌耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23773, encryptionId=555523e73fc, topicName=乳腺癌耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Sun Dec 08 23:21:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852145, encodeId=cc3a1852145da, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 01 00:21:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984514, encodeId=3bd7198451463, content=<a href='/topic/show?id=23002e000b3' target=_blank style='color:#2F92EE;'>#侵袭性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27000, encryptionId=23002e000b3, topicName=侵袭性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Jan 10 11:21:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811220, encodeId=14a5181122076, content=<a href='/topic/show?id=b0558e110be' target=_blank style='color:#2F92EE;'>#英国癌症研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87110, encryptionId=b0558e110be, topicName=英国癌症研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed Dec 18 14:21:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366341, encodeId=9a0813663416d, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Wed Oct 09 01:21:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514195, encodeId=dc181514195a7, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Wed Oct 09 01:21:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557180, encodeId=0678155e180c7, content=<a href='/topic/show?id=f611e7814e8' target=_blank style='color:#2F92EE;'>#细胞分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77814, encryptionId=f611e7814e8, topicName=细胞分裂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126314868296, createdName=wshxjq, createdTime=Wed Oct 09 01:21:00 CST 2019, time=2019-10-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1801064, encodeId=d601180106433, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Mon Dec 02 08:21:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984954, encodeId=d2dd1984954c7, content=<a href='/topic/show?id=d3811218054' target=_blank style='color:#2F92EE;'>#MPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12180, encryptionId=d3811218054, topicName=MPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Dec 16 11:21:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797822, encodeId=aca91e978222a, content=<a href='/topic/show?id=555523e73fc' target=_blank style='color:#2F92EE;'>#乳腺癌耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23773, encryptionId=555523e73fc, topicName=乳腺癌耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Sun Dec 08 23:21:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852145, encodeId=cc3a1852145da, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 01 00:21:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984514, encodeId=3bd7198451463, content=<a href='/topic/show?id=23002e000b3' target=_blank style='color:#2F92EE;'>#侵袭性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27000, encryptionId=23002e000b3, topicName=侵袭性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Jan 10 11:21:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811220, encodeId=14a5181122076, content=<a href='/topic/show?id=b0558e110be' target=_blank style='color:#2F92EE;'>#英国癌症研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87110, encryptionId=b0558e110be, topicName=英国癌症研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed Dec 18 14:21:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366341, encodeId=9a0813663416d, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Wed Oct 09 01:21:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514195, encodeId=dc181514195a7, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Wed Oct 09 01:21:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557180, encodeId=0678155e180c7, content=<a href='/topic/show?id=f611e7814e8' target=_blank style='color:#2F92EE;'>#细胞分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77814, encryptionId=f611e7814e8, topicName=细胞分裂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126314868296, createdName=wshxjq, createdTime=Wed Oct 09 01:21:00 CST 2019, time=2019-10-09, status=1, ipAttribution=)]
    2020-06-01 jklm09
  5. [GetPortalCommentsPageByObjectIdResponse(id=1801064, encodeId=d601180106433, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Mon Dec 02 08:21:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984954, encodeId=d2dd1984954c7, content=<a href='/topic/show?id=d3811218054' target=_blank style='color:#2F92EE;'>#MPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12180, encryptionId=d3811218054, topicName=MPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Dec 16 11:21:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797822, encodeId=aca91e978222a, content=<a href='/topic/show?id=555523e73fc' target=_blank style='color:#2F92EE;'>#乳腺癌耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23773, encryptionId=555523e73fc, topicName=乳腺癌耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Sun Dec 08 23:21:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852145, encodeId=cc3a1852145da, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 01 00:21:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984514, encodeId=3bd7198451463, content=<a href='/topic/show?id=23002e000b3' target=_blank style='color:#2F92EE;'>#侵袭性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27000, encryptionId=23002e000b3, topicName=侵袭性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Jan 10 11:21:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811220, encodeId=14a5181122076, content=<a href='/topic/show?id=b0558e110be' target=_blank style='color:#2F92EE;'>#英国癌症研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87110, encryptionId=b0558e110be, topicName=英国癌症研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed Dec 18 14:21:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366341, encodeId=9a0813663416d, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Wed Oct 09 01:21:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514195, encodeId=dc181514195a7, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Wed Oct 09 01:21:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557180, encodeId=0678155e180c7, content=<a href='/topic/show?id=f611e7814e8' target=_blank style='color:#2F92EE;'>#细胞分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77814, encryptionId=f611e7814e8, topicName=细胞分裂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126314868296, createdName=wshxjq, createdTime=Wed Oct 09 01:21:00 CST 2019, time=2019-10-09, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1801064, encodeId=d601180106433, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Mon Dec 02 08:21:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984954, encodeId=d2dd1984954c7, content=<a href='/topic/show?id=d3811218054' target=_blank style='color:#2F92EE;'>#MPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12180, encryptionId=d3811218054, topicName=MPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Dec 16 11:21:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797822, encodeId=aca91e978222a, content=<a href='/topic/show?id=555523e73fc' target=_blank style='color:#2F92EE;'>#乳腺癌耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23773, encryptionId=555523e73fc, topicName=乳腺癌耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Sun Dec 08 23:21:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852145, encodeId=cc3a1852145da, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 01 00:21:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984514, encodeId=3bd7198451463, content=<a href='/topic/show?id=23002e000b3' target=_blank style='color:#2F92EE;'>#侵袭性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27000, encryptionId=23002e000b3, topicName=侵袭性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Jan 10 11:21:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811220, encodeId=14a5181122076, content=<a href='/topic/show?id=b0558e110be' target=_blank style='color:#2F92EE;'>#英国癌症研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87110, encryptionId=b0558e110be, topicName=英国癌症研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed Dec 18 14:21:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366341, encodeId=9a0813663416d, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Wed Oct 09 01:21:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514195, encodeId=dc181514195a7, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Wed Oct 09 01:21:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557180, encodeId=0678155e180c7, content=<a href='/topic/show?id=f611e7814e8' target=_blank style='color:#2F92EE;'>#细胞分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77814, encryptionId=f611e7814e8, topicName=细胞分裂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126314868296, createdName=wshxjq, createdTime=Wed Oct 09 01:21:00 CST 2019, time=2019-10-09, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1801064, encodeId=d601180106433, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Mon Dec 02 08:21:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984954, encodeId=d2dd1984954c7, content=<a href='/topic/show?id=d3811218054' target=_blank style='color:#2F92EE;'>#MPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12180, encryptionId=d3811218054, topicName=MPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Dec 16 11:21:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797822, encodeId=aca91e978222a, content=<a href='/topic/show?id=555523e73fc' target=_blank style='color:#2F92EE;'>#乳腺癌耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23773, encryptionId=555523e73fc, topicName=乳腺癌耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Sun Dec 08 23:21:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852145, encodeId=cc3a1852145da, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 01 00:21:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984514, encodeId=3bd7198451463, content=<a href='/topic/show?id=23002e000b3' target=_blank style='color:#2F92EE;'>#侵袭性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27000, encryptionId=23002e000b3, topicName=侵袭性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Jan 10 11:21:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811220, encodeId=14a5181122076, content=<a href='/topic/show?id=b0558e110be' target=_blank style='color:#2F92EE;'>#英国癌症研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87110, encryptionId=b0558e110be, topicName=英国癌症研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed Dec 18 14:21:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366341, encodeId=9a0813663416d, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Wed Oct 09 01:21:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514195, encodeId=dc181514195a7, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Wed Oct 09 01:21:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557180, encodeId=0678155e180c7, content=<a href='/topic/show?id=f611e7814e8' target=_blank style='color:#2F92EE;'>#细胞分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77814, encryptionId=f611e7814e8, topicName=细胞分裂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126314868296, createdName=wshxjq, createdTime=Wed Oct 09 01:21:00 CST 2019, time=2019-10-09, status=1, ipAttribution=)]
    2019-10-09 sunyl07
  8. [GetPortalCommentsPageByObjectIdResponse(id=1801064, encodeId=d601180106433, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Mon Dec 02 08:21:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984954, encodeId=d2dd1984954c7, content=<a href='/topic/show?id=d3811218054' target=_blank style='color:#2F92EE;'>#MPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12180, encryptionId=d3811218054, topicName=MPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Dec 16 11:21:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797822, encodeId=aca91e978222a, content=<a href='/topic/show?id=555523e73fc' target=_blank style='color:#2F92EE;'>#乳腺癌耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23773, encryptionId=555523e73fc, topicName=乳腺癌耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Sun Dec 08 23:21:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852145, encodeId=cc3a1852145da, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 01 00:21:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984514, encodeId=3bd7198451463, content=<a href='/topic/show?id=23002e000b3' target=_blank style='color:#2F92EE;'>#侵袭性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27000, encryptionId=23002e000b3, topicName=侵袭性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Jan 10 11:21:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811220, encodeId=14a5181122076, content=<a href='/topic/show?id=b0558e110be' target=_blank style='color:#2F92EE;'>#英国癌症研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87110, encryptionId=b0558e110be, topicName=英国癌症研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed Dec 18 14:21:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366341, encodeId=9a0813663416d, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Wed Oct 09 01:21:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514195, encodeId=dc181514195a7, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Wed Oct 09 01:21:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557180, encodeId=0678155e180c7, content=<a href='/topic/show?id=f611e7814e8' target=_blank style='color:#2F92EE;'>#细胞分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77814, encryptionId=f611e7814e8, topicName=细胞分裂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126314868296, createdName=wshxjq, createdTime=Wed Oct 09 01:21:00 CST 2019, time=2019-10-09, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1801064, encodeId=d601180106433, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Mon Dec 02 08:21:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984954, encodeId=d2dd1984954c7, content=<a href='/topic/show?id=d3811218054' target=_blank style='color:#2F92EE;'>#MPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12180, encryptionId=d3811218054, topicName=MPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Dec 16 11:21:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797822, encodeId=aca91e978222a, content=<a href='/topic/show?id=555523e73fc' target=_blank style='color:#2F92EE;'>#乳腺癌耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23773, encryptionId=555523e73fc, topicName=乳腺癌耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Sun Dec 08 23:21:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852145, encodeId=cc3a1852145da, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 01 00:21:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984514, encodeId=3bd7198451463, content=<a href='/topic/show?id=23002e000b3' target=_blank style='color:#2F92EE;'>#侵袭性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27000, encryptionId=23002e000b3, topicName=侵袭性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Jan 10 11:21:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811220, encodeId=14a5181122076, content=<a href='/topic/show?id=b0558e110be' target=_blank style='color:#2F92EE;'>#英国癌症研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87110, encryptionId=b0558e110be, topicName=英国癌症研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed Dec 18 14:21:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366341, encodeId=9a0813663416d, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Wed Oct 09 01:21:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514195, encodeId=dc181514195a7, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Wed Oct 09 01:21:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557180, encodeId=0678155e180c7, content=<a href='/topic/show?id=f611e7814e8' target=_blank style='color:#2F92EE;'>#细胞分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77814, encryptionId=f611e7814e8, topicName=细胞分裂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126314868296, createdName=wshxjq, createdTime=Wed Oct 09 01:21:00 CST 2019, time=2019-10-09, status=1, ipAttribution=)]